Table 2.

Crude All-Cause Hospitalization Rates, by Day 28, in 1141 Patients With COVID-19 Based on the Clinical Eligibility for Antispike Monoclonal Antibody Therapy as Assessed by the Original (MASS) and Expanded (CAST) FDA EUA Criteria, May and June 2021^a,b

Score	CASTc		MASSd
	No treatment	Casirivimab-imdevimab	No treatment	Casirivimab-imdevimab
1	6.4	3.2	10.6	0
2	12.9	0	13.5	5.9
3	13.5	6.9	25.3	3.7
4	31.0	4.8	22.9	0
≥5	46.9	12.0	40.7	16.7

^aBMI = body mass index; CAST = COVID-19 Antibody Screening Tool; EUA = Emergency Use Authorization; FDA = Food and Drug Administration; MASS = Monoclonal Antibody Screening Score.

^bData are presented as percentage.

^cCOVID-19 Antibody Screening Tool assigned 1 point to each of the expanded US FDA EUA criteria (released in May 2021) as follows: age ≥ 65 y, BMI ≥ 35 kg/m², diabetes mellitus, hypertension, cardiovascular disease, pulmonary disease, dialysis or chronic kidney disease, bone marrow or organ transplant or immunosuppressive medication or disease, pregnancy, sickle cell disease, neurological or neurodevelopmental disorders, genetic or congenital metabolic disorder, liver disease, or use of medical devices.

^dMonoclonal Antibody Screening Score assigned a score to each of the original US FDA EUA criteria (released in November 2020) as follows: age ≥ 65 y (2), BMI ≥ 35 kg/m² (2), diabetes mellitus (2), chronic kidney disease (3), cardiovascular disease in a patient 55 y and older (2), chronic respiratory disease in a patient 55 years and older (3), hypertension in a patient 55 years and older (1), and immunocompromised status (3). The maximum score is 18.